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Introduction Neurodegenerative parkinsonian syndromes have significant 
clinical and pathological overlap, making early diagnosis difficult. Cerebrospinal 
fluid (CSF) biomarkers may aid the differentiation of these disorders, but other 
than α-synuclein and neurofilament light chain protein, which have limited 
diagnostic power, specific protein biomarkers remain elusive. 
Objectives To study disease mechanisms and identify possible CSF diagnostic 
biomarkers through discovery proteomics, which discriminate parkinsonian 
syndromes from healthy controls. 
Methods CSF was collected consecutively from 134 participants; Parkinson’s 
disease (n=26), atypical parkinsonian syndromes (n=78, including progressive 
supranuclear palsy (n=36), multiple system atrophy (n=28), corticobasal 
syndrome (n=14)), and elderly healthy controls (n=30). Participants were 
divided into a discovery and a validation set for analysis. The samples were 
subjected to tryptic digestion, followed by liquid chromatography-mass 
spectrometry analysis for identification and relative quantification by isobaric 
labelling. Candidate protein biomarkers were identified based on the relative 
abundances of the identified tryptic peptides. Their predictive performance was 
evaluated by analysis of the validation set. 
Results 79 tryptic peptides, derived from 26 proteins were found to differ 
significantly between atypical parkinsonism patients and controls. They included 
acute phase/inflammatory markers and neuronal/synaptic markers, which were 
respectively increased or decreased in atypical parkinsonism, while their levels 
in PD subjects were intermediate between controls and atypical parkinsonism. 
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Conclusion Using an unbiased proteomic approach, proteins were identified 
that were able to differentiate atypical parkinsonian syndrome patients from 
healthy controls. Our study indicates that markers that may reflect neuronal 
function and/or plasticity, such as the amyloid precursor protein, and 
inflammatory markers may hold future promise as candidate biomarkers in 
parkinsonism. 
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Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder and the number of patients is expected to double over the next two 
decades, presenting a huge social and economic challenge [1]. Atypical 
parkinsonian syndromes, such as progressive supranuclear palsy (PSP), multiple 
system atrophy (MSA) and corticobasal syndrome (CBS) represent rarer but 
more aggressive forms of parkinsonism. Atypical parkinsonian syndromes and 
PD often present in a strikingly similar manner, making an accurate early 
diagnosis difficult. Despite similar clinical characteristics, these diseases differ 
substantially in their prognosis, pathological features and therapeutic 
response[2, 3]. There is an urgent need to identify biomarkers for parkinsonian 
disorders to enable earlier, accurate diagnosis, monitor disease progression and 
response to drug therapies. 
Cerebrospinal fluid (CSF) has been widely investigated in parkinsonian disorders 
and may serve as a source of biomarkers that reflect brain-related disease 
processes. In PD, clinical studies of candidate proteins, such as α-synuclein and 
neurofilament light chain protein, show minimal changes and high assay 
variability and have thus far not resulted in a diagnostically useful biomarker 
(for a review see[4]). 
To date studies employing unbiased proteomic approaches have led to the 
identification of various combinations of CSF proteins that differ in abundance 
between patient groups[5-9], but singling out promising candidate markers 
among the many detected proteins has proven challenging. Part of the problem is 
the disproportionality of the published proteomic data sets, which contain many 
identified proteins but only few patients, leading to a risk of over-fitting 
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statistical models. Other complicating factors include study groups with 
heterogeneous disease characteristics and experimental variation. 
In order to overcome these limitations, studies of larger patient groups are 
required. While previously limited by the long analysis times of liquid 
chromatography-mass spectrometry (LC-MS) used in discovery proteomics 
workflows, performing large studies is now possible through the development of 
timesaving multiplex isobaric labeling techniques, such as tandem mass tags 
(TMT)[10]. 
In this study, we used multiplex isobaric labeling to perform the largest 
proteomic study of parkinsonism to date, and the first study to include several 
atypical parkinsonian syndromes and healthy controls. Our aim was to shed light 




This is a cross-sectional study of patients with parkinsonian disorders and 
healthy controls. Participants were prospectively enrolled over a two-year 
period from 2011 to 2013 from the movement disorders, cognitive and 
autonomic disorders clinics at the National Hospital for Neurology and 
Neurosurgery, Queen Square, London. The diagnoses of probable PD, PSP, CBS 
and MSA were based on consensus operational criteria[3, 11-13]. 
Patients included in the study were 40-85 years old and under follow-up for at 
least two years. The clinical diagnosis was corroborated by at least two 
neurologists with experience in movement disorders (AJL, TTW, HRM, AJN, NM). 
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Further information patient characterization and exclusion criteria are listed in 
“Supplementary Materials – Methods”. 
Ethics Approval 
The study was conducted in accordance with local clinical research regulations 
and an informed consent was obtained from all subjects, including access to 
clinical data and imaging. The study was performed in accordance with the 
provisions of the Helsinki declaration and the research protocol was approved 
by the London Queen Square research ethics committee. 
CSF Collection and Storage 
We adhered to a standardized protocol for the collection and storage of CSF as 
recommended by the Alzheimer’s Association QC Program for AD CSF 
biomarkers (www.neurochem.gu.se/TheAlzAssQCProgram). Details on the 
procedure are given in “Supplementary Materials – Methods”. 
Experimental Design 
136 subjects were included in the analysis. Subjects were randomly divided into 
a discovery (13 PD, 39 atypical parkinsonian patients and 15 healthy controls) 
and a validation (13 PD, 43 atypical parkinsonian patients and 13 healthy 
controls) set. For demographic and clinical characteristics see Table 1. CSF 
samples from the two sets were prepared and analyzed separately. Details of CSF 
sample preparation are provided in “Supplementary Materials- Methods”. 
MS analysis 
The samples were reconstituted in a solution of 2% acetonitrile, 0.1% TFA (600 
µl). Aliquots of 2 µl were analyzed with a nano-LC (Ultimate 3000, Thermo 
Scientific) equipped with a C18 trap column (PepMap Acclaim 75 µm *20 mm, 
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Thermo Scientific), and a C18 separation column (PepMap Acclaim 75 µm * 500 
mm, Thermo Scientific), coupled to a Q-Exactive electrospray ionization mass 
spectrometer (Thermo Scientific), fitted with a FlexiSpray ion source. The 
loading buffer was 2% acetonitrile, 0.05% TFA; Buffer A was 0.1% formic acid; 
and Buffer B was 84% acetonitrile, 0.1% formic acid. The following gradient was 
used: t=0 min, B=3%; 140 min, B=30%; 160 min, B=45%; 165 min, B=80%. The 
mass spectrometer was operated in the positive ion mode. Data-dependent 
acquisition was used, acquiring one full MS scan (R=70k, AGC target=1e6, max 
IT=250 ms) and up to 10 consecutive MS/MS scans (R=17.5k, AGC target=5e4, 
max IT=60 ms). Data processing was performed within the software 
ProteomeDiscoverer 1.4 (Thermo Scientific), using Mascot (MatrixScience) for 
protein identification (precursor ∆m tolerance=5 ppm, fragment ∆m 
tolerance=20 milli mass units, missed cleavages=2, fixed 
modifications=carbamidomethylation, variable modifications=oxidation of 
methionine), searching the human subset of the UniProtKB Swiss-Prot database 
(release 13-10) (www.uniprot.org). Percolator (MatrixScience) was used for 
scoring peptide specific matches, and 1% false discovery rate (FDR) was set as 
threshold for identification. The following settings were used for reporter ion 
quantification: Integration tolerance=150 ppm; Integration Method= Most 
Confident Centroid; exclusion of MS/MS spectra >50% co-isolation; normalize on 
protein median. 
Data analysis 
Statistical data analysis was performed using R Statistics, with the libraries 
pROC[14] and ggplot2[15]. T-tests were performed on log-transformed TMT 
reporter ion ratios of peptides detected in >50% of the samples to assess the 
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significance of differences in the relative abundance of the peptides between the 
patient groups and the controls in the discovery set. The p-values were corrected 
for multiple testing according to Benjamini-Hochberg[16]. Peptides with p<0.05 
were considered significant. These were evaluated in the validation set, applying 
the same methods and criteria as for the discovery set, considering, for multiple 
testing correction, the t-tests performed in the validation set.  Spearman’s rank 
correlation coefficient was used to evaluate the correlation between the 
identified biomarker candidates and age. 
Results 
Demographic characteristics of the participants in the study are given in Table 1. 
Mass spectrometric analysis of the discovery set identified 5043 tryptic peptides, 
out of which 1689 were detected in >50% of the participants. Ninety peptides 
had significantly (p<0.05) different abundances in atypical parkinsonian 
syndromes versus healthy controls. Out of these, 89 were also detected in >50% 
of the patients in the validation set. In the validation set, 80 out of the 89 
peptides differed significantly (p<0.05) in abundance between atypical 
parkinsonian syndromes and healthy controls. Between the two sets, all 80 
differed in the same direction. The median difference in percentage points for 
the peptides between the two sets was 5% (max. 42%, min. 1%). The relative 
abundance of one peptide, belonging to complement component C7, correlated 
significantly with age (p= 0.0074), and was therefore disqualified as a candidate 
biomarker. In total, 79 tryptic peptides, belonging to 26 proteins were identified 
as candidate biomarkers of atypical parkinsonian syndromes (Supplementary 
Table s1, Figure 1).  
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Pathologically confirmed group 
Since the study began 11 patients have died and donated their brains for 
pathological examination. Six PSP, three MSA and two CBS patients were 
diagnosed according to standard pathological criteria. Two of the eleven patients 
were misclassified during life (one patient was clinically diagnosed with PSP and 
had CBS pathology, and one was clinically diagnosed with MSA and had PSP 
pathology).   
Discussion 
The 26 proteins identified that differed between healthy controls and patients 
with atypical parkinsonian syndromes fit into three categories: acute 
phase/inflammatory (which were significantly increased in atypical 
parkinsonian syndromes) and neuronal/synaptic proteins or proteins involved 
in cancer/metastasis formation (which were significantly decreased in atypical 
parkinsonian syndromes compared with healthy controls) (Table 2). For all 
proteins, the levels in PD were intermediate between healthy controls and 
atypical parkinsonian syndromes, which may reflect the slower and less 
widespread neurodegeneration in PD compared to more aggressive forms of 
parkinsonism. This trend was strongest for the acute phase/inflammatory 
proteins, whereas among the neuronal/synaptic proteins there were several that 
are more specific to atypical parkinsonian syndromes. 13 proteins had AUC 
values between 0.70 and 0.80, which is similar to earlier reported AUCs for CSF 
neurofilament light chain protein and better than what can be achieved using 
CSF α-synuclein[17, 18]. 
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Description of Proteins Identified and Previous CSF Neurodegenerative 
Studies 
A summary of the known functions of each protein identified is given in Table S2 
in Supplementary Material online.  A literature review revealed that 22 out of 
those 26 proteins have already been described in previous CSF studies in 
neurodegenerative diseases. 16 proteins were previously identified in studies 
involving parkinsonian groups and 15 proteins were previously identified in 
proteomic studies. Eight proteins have been found in published proteomics 
studies involving parkinsonian groups. 
Acute phase/Inflammatory Proteins 
Neuroinflammation is a critical component in the progression of many 
neurodegenerative diseases. We reproduced published results showing 
alteration in CSF proteome of parkinsonian patients for proteins involved in 
immune response.  
The complement system consists of over 30 proteins and is an important 
member of both the innate and adaptive immune systems[19]. Inappropriate 
activation of complement can contribute to disease. A proteomics study 
investigated serum taken from patients with PD, amyotrophic lateral sclerosis 
(ALS), neurological and healthy controls[20]. PD and ALS patients showed a 
marked increase in seven out of nine complement related proteins. This is 
consistent with what was demonstrated in our study where atypical 
parkinsonian patients had significantly increased CSF levels of complements C9 
and factor H compared with healthy controls. 
A recent study from our group using a commercially available enzyme-linked 
immunosorbent assay (ELISA)[17] showed increased CSF levels of YKL-40 in 
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atypical parkinsonian syndromes (especially PSP), with lowest levels in healthy 
controls (PD levels were slightly higher than controls). In our current study, 
using a mass-spectrometry approach, we find further supportive evidence for 
elevated YLK-40 in atypical parkinsonian syndromes.  
CSF α-1-antichymotrypsin (ACT) levels have been reported as being significantly 
increased in MSA compared with neurological controls[21]. Here we also report 
significantly increased CSF ACT levels in atypical parkinsonian patients 
compared with healthy controls.  
Neuronal/Synaptic Proteins 
Recently, secretogranin2 gene was established as a signal integrator of glutamate 
and dopamine inputs[22]. A previous proteomics study has demonstrated that 
using two secretogranin 1 fragments and two other markers, PD and healthy 
controls could be differentiated from atypical parkinsonian patients[6]. We have 
replicated these findings by showing significantly reduced CSF secretogranin 1-3 
levels in atypical parkinsonian subjects, differentiating them from healthy 
controls.  
In another proteomics study, CSF neuronal pentraxin receptor (NPR) was found 
to be significantly decreased in PD compared with healthy controls[23]. We also 
found reduced CSF NPR levels in PD compared with healthy controls, but the 
most significant decrease was again in the atypical parkinsonian group. 
Our data showed reduced CSF levels of all proteins associated with APP in 
atypical parkinsonian patients compared with healthy controls. This is 
consistent with our recent findings using commercially available ELISAs[17], 
which demonstrated significantly decreased levels of soluble APPα and β in 
atypical parkinsonian patients compared with PD and healthy controls. Amyloid-
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like protein 1 (APLP1) has a probable role in synaptogenesis or synaptic 
maturation[24]. In a recent proteomics study, CSF APLP1 was found to be 
significantly reduced in PD compared with patients with Alzheimer’s disease and 
healthy controls[25]. Calsyntenin-1 contributes to the axonal transport of APP. 
Using proteomics technology, CSF calsyntenin 1 (isoform 2) was found to be 
decreased in PD compared with healthy controls[23].  
The reason for the APP reduction is unclear but it is interesting to note that APP 
is bound to the mitochondrial outer membrane and has been implicated in 
mitochondrial dysfunction, which may contribute to some neurodegenerative 
diseases[26].  
Decreased levels of somatostatin have been found in CSF of parkinsonian 
patients[27] compared with AD patients and elderly controls, which is in 
accordance with our data. In another proteomics study, CSF neuronal cell 
adhesion molecule was found to be decreased in PD compared with healthy 
controls[23]. Even though the most significant decrease in neuronal cell 
adhesion molecule levels in our study was in atypical parkinsonian syndromes, 
PD levels were also lower compared to healthy controls.  
Proteins associated with cancer/metastasis formation 
The pathogenesis of both neurodegenerative and carcinogenic diseases is due to 
a constellation of genetic and environmental factors. Causative genes have been 
found to be involved in both processes usually showing an inverse correlation 
between the risk of developing cancer and a neurodegenerative disorder, 
especially PD[28]. Many of the genes associated with cancer and 
neurodegeneration have a central role in cell cycle control, DNA repair and 
kinase signaling[28].In addition, post-translation modifications play an 
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important role in both cancer and neurodegeneration. For example, loss of 
function of Parkin (PARK2) gene leads to PD[29] and Parkin in cancer acts as 
tumour suppressor.[30] In our study, we have found four proteins associated 
with cancer/metastasis formation, the precursor of one of which, FAM3C, has 
already been identified in another proteomics study as a potential CSF 
biomarker in dementia with Lewy bodies (DLB)[5]- a synucleinopathy closely 
linked to PD.  
Genome-Wide Association (GWA) studies 
Recent observations from GWA studies of PSP patients compared to controls 
provide further insight at a genomic level[31]. For PSP, genome wide significance 
was found for single nucleotide polymorphisms (SNPs) in the region of the MAPT 
gene (aggregated tau as neurofibrillary tangles and coiled bodies are 
pathological hallmark of PSP), and in the regions of STX6 (involved in synaptic 
transmission and vesicular trafficking) and EIF2AK3 (which localizes to the 
endoplasmic reticulum and is involved in the unfolded protein response). 
Significance was also reported in the region of MOBP gene (which has a less well 
defined role but relates to either myelin or oligodendrocytes). Our finding of 
significant change in a number of synaptic proteins in the atypical parkinsonian 
syndromes aligns with mounting evidence of pathways in vesicular transport 
and synaptic transmission being vital in the pathogenesis of PSP.  
Differentiation between PD and APS 
To assess the diagnostic potential of the identified candidate markers, we 
performed ROC curve analysis between the disease groups. We found five 
proteins with AUC values between 0.73 and 0.80 differentiating between PD and 
atypical parkinsonian groups. They included α-1-antichymotrypsin, 
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secretogranin 1-3, endothelin B receptor like protein 2 and neuronal pentraxin 
receptor. These predominantly neuronal/synaptic proteins could be promising 
diagnostic biomarkers. 
Strengths  
This is the most comprehensive proteomic study of parkinsonian syndromes to 
date. The study design is robust as both a discovery and validation set were used 
and analyzed separately. Randomly splitting the original sample of subjects, 
using one database as a training set to create the predictor and the remainder of 
subjects for validation is used in order to overcome the common proteomics 
studies’ problem of overfitting the model[32]. Our diseased groups are well 
defined and were followed up for at least two years after inclusion into the study, 
improving the accuracy of the clinical diagnoses. For 13% of the atypical 
parkinsonian patients, there is pathological confirmation. The number of 
identified proteins was considerably higher compared to the other proteomics 
study in parkinsonian conditions. The statistical data analysis method employed 
was unbiased and all 26 candidate biomarkers identified in atypical 
parkinsonian syndromes vs. healthy controls can be interpreted within the 
framework of neurodegeneration. 22 out of those 26 proteins have already been 
described in previous CSF neurodegenerative studies and 15 proteins were 
identified in studies also using proteomics technology. Thus we have found 
significant overlap with previous CSF proteomics studies in neurodegenerative 
diseases.  
Abdi et al compared relative changes in the CSF proteome among with 10 AD, 10 
PD and 5 DLB compared with 10 healthy controls. They found 136 proteins 
uniquely associated with AD, 72 with PD and 101 with DLB[5]. However, this 
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study included small numbers of patients and lacked a validation group. 
Nevertheless, there was overlap with six of the proteins identified in our study: 
neuronal pantraxin 1, APP, APLP2, FAM3C, neuroblastoma suppressor of 
tumerigenicity 1 and probable G-protein coupled receptor 158. 
To our knowledge, Constantinescu’s study[6] is the only proteomics study in the 
literature with comparable diseased groups to ours (PD n=56, MSA n=42, PSP 
n=36, CBD n=9) and 24 healthy controls. They concluded that a CSF proteomic 
profile consisting of four proteins (ubiquitin, β2-microglobulin and two 
secretogranin 1 fragments) could differentiate PD and healthy controls from 
atypical parkinsonian patients with an AUC of 0.8.  Constantinescu et al used 
profiling based methods that lack the dynamic range to detect differences other 
than those seen for relatively abundant proteins. Nevertheless, there was an 
overlap with one protein identified in our study- secretogranin 1. Constantinescu 
et al could not differentiate between PD patients and controls. In our study, using 
more advanced proteomics technology, we were able to show some degree of 
differentiation between PD and healthy controls, even though the greatest 




A recurring challenge in the study of neurodegenerative disorders is clinical 
misdiagnosis of patients. In our pathologically confirmed patient group, two out 
of 11 atypical parkinsonian patients were misdiagnosed during life. Another 
challenge is controls, who are healthy at the inclusion of the study, but may 
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develop neurodegenerative conditions that become clinically apparent years 
later. In our study, there were aberrant values for several peptides from the 
same healthy control. Within two years of inclusion in the study she developed 
mild cognitive problems- she is distractible and her manager at work has noticed 
a decline in her performance; so she may be at the early stages of a 
neurodegenerative disorder. We included her as a healthy control in the 
statistical analysis. 
Furthermore, we did not validate the identified proteins using an alternative 
method, such as conventional immunoassays. We are planning to do this at a 
future study. Finally, the panel of candidate biomarkers in parkinsonism 
identified in our study does not contain several established biomarkers, such as 
α-synuclein or neurofilament light chain protein[4]. More extensive sample 
prefractionation prior to LC-MS, to increase the CSF volume that can be analyzed 
while simplifying the peptide mixture loaded, will be necessary to detect such 
lower abundant proteins. 
Conclusions 
Using an unbiased approach we identified proteins differentiating parkinsonian 
patients from healthy controls. They mainly consist of inflammatory, neuronal 
and synaptic markers and they may give new clues for disease mechanisms of 
neurodegeneration in parkinsonism, and provide valuable biomarkers for more 
accurate and expedient diagnosis. 
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Table 1. Demographic and clinical characteristics in the study groups. 
Abbreviations: avg: average, dis dur: disease duration, H&Y score: Hoehn and 
Yahr score, HC: healthy controls, PD: Parkinson’s disease, APS: atypical 
parkinsonian syndromes 
 
Table 2: Classification of identified proteins in CSF proteome of atypical 
parkinsonian patients vs. healthy controls. 
Abbreviations: APS: atypical parkinsonian syndrome, APP: amyloid precursor 
protein, FAM3C:  family with sequence similarity 3C protein, /: consistent 
increase/decrease of quantified tryptic peptides. 
Figure legends 
Figure 1. Group separation of the identified candidate biomarkers. The scale on 
the Y-axis is the Log2-transformed TMT-reporter ion ratios. Data are plotted for 
one tryptic peptide per protein. Abbreviations: HC: healthy controls, PD: 
Parkinson’s disease, APS: atypical parkinsonian syndrome. Abbreviations: CSF: 
cerebrospinal fluid, TMT: tandem mass tags, LC-MS: liquid chromatography mass 
spectrometry, MS/MS: tandem mass spectrometry.  
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Supplementary Table Legends 
Table s1. Cerebrospinal fluid candidate biomarkers identified in atypical 
parkinsonism. 
The relative difference was calculated as the median relative difference for all 
tryptic peptides detected for each protein in both the Discovery and Validation 
set. The p-values were calculated by t-test, comparing APS and HC in the 
Validation set. The reported p-value for each protein is the lowest p-value for a 
tryptic peptide from the protein. AUC-values were obtained by ROC-curve 
analysis. Abbreviations: PD: Parkinson’s Disease, APS: atypical parkinsonian 
syndrome, HC: healthy controls. 
 
Table S2: Description of identified proteins and outline of previous CSF studies 
involving these proteins in neurodegenerative diseases. 
 
